Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus

被引:21
作者
Delagrave, S
Catalan, J
Sweet, C
Drabik, G
Henry, A
Rees, A
Monath, TP
Guirakhoo, F
机构
[1] Hercules Inc, Wilmington, DE 19808 USA
[2] Oxford Mol Ltd, Medawar Ctr, Oxford OX4 4GA, England
[3] Univ Bath, Sch Biol & Biochem, Bath BA2 7AY, Avon, England
来源
PROTEIN ENGINEERING | 1999年 / 12卷 / 04期
关键词
antibody; immunotherapy; resurfacing; single-chain Fv;
D O I
10.1093/protein/12.4.357
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HNK20 is a mouse monoclonal IgA that binds to the F glycoprotein of respiratory syncytial virus (RSV) and neutralizes the virus, both lit vitro and irt vivo. The single-chain antibody fragment (scFv) derived from HNK20 is equally active and has allowed us to assess rapidly the effect of mutations on affinity and antiviral activity. Humanization by variable domain resurfacing requires that surface residues not normally found in a human Fv be mutated to the expected human amino acid, thereby eliminating potentially immunogenic sites. We describe the construction and characterization of two humanized scFvs, hu7 and hu10, bearing 7 and 10 mutations, respectively. Both molecules show unaltered binding affinities to the RSV antigen (purified F protein) as determined by ELISA and surface plasmon resonance measurements of binding kinetics (K-a approximate to 1x10(9) M-1). A competition ELISA using captured whole virus confirmed that the binding affinities of the parental scFv and also of hu7 and hu10 scFvs were identical. However, when compared with the original scFv, hu10 scFv was shown to have significantly decreased antiviral activity both in vitro and in a mouse model. Our observations suggest that binding of the scFv to the viral antigen is not sufficient for neutralization. We speculate that neutralization may involve the inhibition or induction of conformational changes in the bound antigen, thereby interfering with the F protein-mediated fusion of virus and cell membranes in the initial steps of infection.
引用
收藏
页码:357 / 362
页数:6
相关论文
共 24 条
[1]   MICRONEUTRALIZATION TEST FOR RESPIRATORY SYNCYTIAL VIRUS BASED ON AN ENZYME-IMMUNOASSAY [J].
ANDERSON, LJ ;
HIERHOLZER, JC ;
BINGHAM, PG ;
STONE, YO .
JOURNAL OF CLINICAL MICROBIOLOGY, 1985, 22 (06) :1050-1052
[2]   MUTATIONS CONFERRING RESISTANCE TO NEUTRALIZATION WITH MONOCLONAL-ANTIBODIES IN TYPE-1 POLIOVIRUS CAN BE LOCATED OUTSIDE OR INSIDE THE ANTIBODY-BINDING SITE [J].
BLONDEL, B ;
CRAINIC, R ;
FICHOT, O ;
DUFRAISSE, G ;
CANDREA, A ;
DIAMOND, D ;
GIRARD, M ;
HORAUD, F .
JOURNAL OF VIROLOGY, 1986, 57 (01) :81-90
[3]   PREDICTION OF THE FOLDING OF SHORT POLYPEPTIDE SEGMENTS BY UNIFORM CONFORMATIONAL SAMPLING [J].
BRUCCOLERI, RE ;
KARPLUS, M .
BIOPOLYMERS, 1987, 26 (01) :137-168
[4]   STRUCTURAL REPERTOIRE OF THE HUMAN V(H) SEGMENTS [J].
CHOTHIA, C ;
LESK, AM ;
GHERARDI, E ;
TOMLINSON, IM ;
WALTER, G ;
MARKS, JD ;
LLEWELYN, MB ;
WINTER, G .
JOURNAL OF MOLECULAR BIOLOGY, 1992, 227 (03) :799-817
[5]   HUMANIZED ANTIBODIES FOR ANTIVIRAL THERAPY [J].
CO, MS ;
DESCHAMPS, M ;
WHITLEY, RJ ;
QUEEN, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (07) :2869-2873
[6]   INHIBITION OF RHINOVIRUS ATTACHMENT BY NEUTRALIZING MONOCLONAL-ANTIBODIES AND THEIR FAB FRAGMENTS [J].
COLONNO, RJ ;
CALLAHAN, PL ;
LEIPPE, DM ;
RUECKERT, RR ;
TOMASSINI, JE .
JOURNAL OF VIROLOGY, 1989, 63 (01) :36-42
[7]   HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer [J].
Disis, ML ;
Cheever, MA .
ADVANCES IN CANCER RESEARCH, VOL 71, 1997, 71 :343-371
[8]   FUNCTIONAL BASIS OF POLIOVIRUS NEUTRALIZATION DETERMINED WITH MONOSPECIFIC NEUTRALIZING ANTIBODIES [J].
EMINI, EA ;
KAO, SY ;
LEWIS, AJ ;
CRAINIC, R ;
WIMMER, E .
JOURNAL OF VIROLOGY, 1983, 46 (02) :466-474
[9]   Cloning, expression and functional activities of a single chain antibody fragment directed to fusion protein of respiratory syncytial virus [J].
Guirakhoo, F ;
Catalan, J ;
Monath, T ;
Weltzin, R .
IMMUNOTECHNOLOGY, 1996, 2 (03) :219-228
[10]   A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections [J].
Hamilton, AA ;
Manuel, DM ;
Grundy, JE ;
Turner, AJ ;
King, SI ;
Adair, JR ;
White, P ;
Carr, FJ ;
Harris, WJ .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (01) :59-68